CCFM
CRSP icon

Clear Creek Financial Management’s CRISPR Therapeutics CRSP Stock Holding History

Clear Creek Financial Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,679
Closed -$300K – 250
2020
Q1 		$300K Buy
5,679
+150
+3% +$7.75K 0.11% 116
2019
Q4 		$332K Hold
5,529
– – 0.13% 86
2019
Q3 		$311K Sell
5,529
-701
-11% -$33.5K 0.15% 80
2019
Q2 		$293K Buy
+6,230
New +$249K 0.13% 91

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Clear Creek Financial Management's CRSP Position: Q2 2020 in Review

Clear Creek Financial Management sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 5,679 shares — an estimated $300K sold.

Clear Creek Financial Management first reported a position in CRSP in Q2 2019 and held it in 4 quarters. The position peaked at $332K in Q4 2019. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • Clear Creek Financial Management reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Clear Creek Financial Management sold 5,679 CRISPR Therapeutics shares in Q2 2020, an estimated $300K.
  • Clear Creek Financial Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 4 quarters.
  • Clear Creek Financial Management's CRISPR Therapeutics position peaked at $332K in Q4 2019.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Clear Creek Financial Management's 13F filing for Q2 2020, filed 16 Jul 2020.